Sugi Predict

Sugi Predict / Compounds / SCHEMBL4776802

SCHEMBL4776802

SCHEMBL4776802

COC(=O)c1ccc(N(Cc2cccc(Cl)c2Cl)S(=O)(=O)NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.43
▸ LMNA P02545 2/20 0.43
▸ REN P00797 1/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ CA12 O43570 2/20 0.36
▸ CA1 P00915 2/20 0.36
▸ CA7 P43166 2/20 0.36
▸ CA14 Q9ULX7 2/20 0.36
▸ GAA P10253 2/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NOTUM Q6P988 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768089 0.87 MAPT (0.47) MAPTLMNASMN1; SMN2CYP1A2TSHR
SCHEMBL4773376 0.85 MAPT (0.48) MAPTLMNASMN1; SMN2CYP1A2TSHR
SCHEMBL4776409 0.84 MAPT (0.48) MAPTLMNASMN1; SMN2CYP1A2TSHR
SCHEMBL4770776 0.84 MAPT (0.46) MAPTLMNARENSMN1; SMN2CYP1A2
SCHEMBL4773418 0.84 MAPT (0.45) MAPTLMNASMN1; SMN2TSHRRAB9A
SCHEMBL4775041 0.83 MAPT (0.51) MAPTLMNASMN1; SMN2CYP1A2TSHR
SCHEMBL4777409 0.82 ALDH1A1 (0.51) MAPTLMNASMN1; SMN2CYP1A2TSHR
SCHEMBL4776855 0.82 MAPT (0.45) MAPTLMNASMN1; SMN2CYP1A2TSHR
SCHEMBL4776454 0.81 ALDH1A1 (0.46) MAPTLMNARENSMN1; SMN2ALDH1A1
SCHEMBL4768135 0.81 MAPT (0.49) MAPTLMNASMN1; SMN2CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 — — EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 — — US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 — — WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 — — EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 — — US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 MAPT 294/4885LMNA 1022/4885REN 4180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.